Presentation Data Exclusivity Market Protection

Q12 Step 2b Technical and regulatory …

ICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36

  Product, Management, Lifecycle, Product lifecycle management

Guideline on good pharmacovigilance practices …

9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline on good pharmacovigilance practices (GVP)

Guideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25

  Good, Practices

Guideline on good pharmacovigilance practices …

Guideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

Guideline for good clinical practice E6(R2)

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification

  Good, Practices, Clinical, Good clinical practice

Guideline for good clinical practice E6(R2)

Guideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November

  Guidelines, Good, Practices, Clinical, Good clinical practice e6

Guideline on good pharmacovigilance practices …

harmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product

  Guidelines, Good, Practices, Guideline on good pharmacovigilance practices, Pharmacovigilance

European Medicines Agency

© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline

  Guidelines, European, Agency, Medicine, Harmonised, European medicines agency, Ich harmonised

products1/traditional herbal medicinal products

There is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already

  Product, Medicinal, Traditional, Herbal, Products1 traditional herbal medicinal products, Products1

Q7 Q&A - good manufacturing practice for active ...

ICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37

  Good, Practices, Pharmaceutical, Manufacturing, Active, Ingredients, Good manufacturing practice for active, Good manufacturing practice for active pharmaceutical ingredients

Thesis Defense Presentations Outline STUDENT

Title: Microsoft Word - Thesis Defense Presentations_Outline_STUDENT.docx Created Date: 3/2/2015 3:40:32 PM

COVID-19 vaccine safety update - Centers for Disease ...

Summary of v-safe data Pfizer-BioNTech Moderna All COVID-19 vaccines People receiving 1 or more doses in the United States * 12,153,536 9,689,497 21,843,033 Registrants completing at least 1 v-safe health check-in † 997,042 1,083,174 2,080,216 Pregnancies reported to v-safe 8,633 6,498 15,131 * COVID Data Tracker data as of 1/24/2021 †

  Data

COVID-19 Vaccines in Adults: Benefit-Risk Discussion

Jul 22, 2021 · severity data (through June 19. th) • VE for hospitalization (95%) • VE for COVID-19 symptomatic cases (95%) • 120-y periodda. Potential harms Estimated cases of . myocarditis. per 1 million second doses of mRNA COVID-19 vaccine, by age/sex using data from VAERS through June 30, 2021. Methods for assessment of benefit-risk balance –

  Data

Q4 2021 Results - novartis.com

This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Refo rm Act of 1995, that can generally be identified by words such as “potential,” “expected,” “will,” “planned,” “pipeline,” “outlook,” or similar expressions, or …

  Presentation, Novartis

DATA ANALYSIS, INTERPRETATION AND PRESENTATION

analysis to use on a set of data and the relevant forms of pictorial presentation or data display. The decision is based on the scale of measurement of the data. These scales are nominal, ordinal and numerical. Nominal scale A nominal scale is where: the data can be classified into a non-numerical or named categories, and

  Data, Presentation, Of data